Kiziltan ME, Gunduz A, Kiziltan G, et al. Peripheral neuropathy in patients with diabetic foot ulcera: clinical and nerve conduction study. J Neurol Sci 2007; 258: 75–9PubMedCrossRef 26. Shaikh AS, Somani RS. Animal models and biomarkers of neuropathy in diabetic rodents. Indian J Pharmacol 2010; 42 (3): 129–34PubMedCrossRef 27. Edwards JL, Vincent CH5424802 chemical structure AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol

Ther 2008; 120: 1–34PubMedCrossRef 28. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21: 114–21PubMedCrossRef 29. Vincent AM, Russell JW, Sullivan KA, et al. SOD2 protects neurons Acalabrutinib mouse from injury in cell culture and animal models of diabetic neuropathy. Exper Neurol 2007; 208: 216–27CrossRef 30. Ziegler D. Painful diabetic neuropathy. Diabetes Care 2009; Suppl. 2 (32): S414–9CrossRef”
“Introduction Asthma disproportionately affects racial and ethnic populations. In the US in 2006, the age-adjusted, asthma-related mortality rates were approximately 3 times higher in non-Hispanic Blacks than in non-Hispanic Whites and Hispanics.[1] Although typical safety

and efficacy studies are underpowered or too short in duration to make definitive conclusions regarding severe asthma exacerbations (i.e. those requiring systemic corticosteroids), important insight into the efficacy of medications can be gained from analyzing related moderate exacerbation events characterized by a sustained loss of asthma control (beyond normal day-to-day SPTBN5 variation) that does not meet the definition of a severe exacerbation.[2] For the purpose of asthma research protocol development, moderate exacerbation events

have been captured using various terminology, such as asthma deterioration,[3] asthma worsenings,[4] and asthma events.[5] Few US studies have evaluated the safety and efficacy of an inhaled corticosteroid (ICS)/long-acting β2-adrenergic agonist (LABA) combination therapy in Black or Hispanic patients with asthma. The efficacy of budesonide/formoterol (BUD/FM) pressurized metered-dose inhaler (pMDI) has been evaluated in randomized, double-blind studies in predominantly White patients with mild to moderate asthma[6] and predominantly White,[5] Black,[7] and Hispanic[8] patients with moderate to severe asthma. Results for a predefined asthma event definition, which encompass moderate to severe asthma deteriorations, are presented as these findings have not been presented previously in detail or compared across patient populations. Methods Table I includes a brief summary of the studies that were included in this exploratory analysis. Additional details of the individual studies, including study design and methods, have been previously described.